AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringers
Description: Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
Study NCT05241054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head-up tilt
Description: The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
Study NCT06098144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Counseling
Description: The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes.
Study NCT06098144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Counseling
Description: Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
Study NCT04935008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The recruitment maneuver
Description: In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
Study NCT06079203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergency Care Redesign (ECR)
Description: Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services
Study NCT06079203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Telephonic Care (NLTC)
Description: Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call \~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
Study NCT06079203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Paramedic-led Transitions Intervention (CPTI)
Description: Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within \~5 days of index ED visit. One home visit and three telephone encounters over 30 days
Study NCT00938990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Study NCT00938990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT05167513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / Sitagliptin Oral Tablet
Description: Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes.
Study NCT05122533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EOS
Description: EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
Study NCT05122533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical limb length measurements
Description: Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position
Study NCT00693342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunological adjuvant OPT-821
Description: Given subcutaneously
Study NCT00693342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: polyvalent antigen-KLH conjugate vaccine
Description: Given subcutaneously
Study NCT05668104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jing Si Herbal Tea Liquid Packet
Description: The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
Study NCT05668104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Jing Si Herbal Tea Liquid Packet Placebo
Description: Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
Study NCT05403528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 3D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
Study NCT05403528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-3D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
Study NCT05403528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
Study NCT06238713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques
Description: Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
Study NCT06238713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques
Description: Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
Study NCT06034379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSpectacle Clinical prototype (CP1) device
Description: The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
Study NCT06034379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
Study NCT04865939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sterile water irrigation
Description: Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
Study NCT04865939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 300 mcg
Description: buprenorphine for 300mcg buccal administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 600 mcg
Description: buprenorphine for 600mcg buccal administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 900 mcg
Description: buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Placebo
Description: Placebo for buccal administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buccal Placebo
Description: Placebo for buccal administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo for oral administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo for oral administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral immediate-release oxycodone 10mg
Description: Immediate-release oxycodone for 10 mg oral administration
Study NCT05988710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 450mcg
Description: buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
Study NCT05859022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric By-pass (RYGB) surgery
Description: RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.
Study NCT05859022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bariatric Arterial Embolization (BAE) procedure
Description: use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
Study NCT06036784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 1416 (Part A)
Description: Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
Study NCT06036784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 1416 (Part B)
Description: Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
Study NCT06036784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose or repeated subcutaneous (SC) dose of placebo.
Study NCT06036784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 1416 (Part C)
Description: Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
Study NCT05600062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril 100 milligram (MG) Oral Capsule
Description: Licensed NEP inhibitor
Study NCT05600062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT06167642 — intervention group
Intervention type: DRUG
Intervention: Ofatumumab
Description: Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
Study NCT06032520 — intervention group
Intervention type: BEHAVIORAL
Intervention: FAST
Description: FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
Study NCT05914038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
Study NCT05914038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
Study NCT04962828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vocabulary based intervention- Non Collaborative
Description: List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks Only with SLP
Study NCT04962828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vocabulary based intervention - Collaborative
Description: List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks With SLP and to be reinforced by teachers in class over the week
Study NCT06507631 — intervention group
Intervention type: BEHAVIORAL
Intervention: Blended care pirate group
Description: During the blended care pirate group, children will receive training while their less affected arm is in a sling. They will perform play-like activities with their affected arm both on-site and at home.
Study NCT05539261 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field
Study NCT05539261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test
Study NCT05112094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral magnetic stimulation
Description: peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
Study NCT05112094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
Study NCT05112094 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy
Description: regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
Study NCT06294015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% ASED + AT
Description: Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.
Study NCT06294015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NS + AT
Description: Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.
Study NCT04837599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discovery TM of Pentax medical on/off in colonoscopy
Description: on the monitor artificial integlligence Discovery can be switched on or off.
Study NCT04788875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small bite suturing Technique
Description: Small bite suturing technique with PDS 2.0
Study NCT04788875 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardised Large Bites Technique
Description: Standardised large bite suturing technique with PDS 2.0
Study NCT05149573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
Study NCT05149573 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Electromagnetic Field (PEMF) Device
Description: The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
Study NCT05550714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
Study NCT05550714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conscious sedation
Description: A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
Study NCT04858594 — intervention group
Intervention type: OTHER
Intervention: Planned Chemotherapy
Description: standard oncologic supportive care including antibiotic prophylaxis
Study NCT05834790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Augmented Reality (MAR) for oral health education program
Description: MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program
Study NCT05834790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture-based oral health education program
Description: The oral health education program that will be delivered by traditional lecture-based process
Study NCT05682495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
Study NCT05682495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
Study NCT05682495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM C
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
Study NCT05682495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM D
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
Study NCT05682495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM E
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
Study NCT05682495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM F
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.